Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme

NCT00102648 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00102648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 21, 2004
Completion date
December 1, 2025
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant supratentorial neoplasm, recurrent glioblastoma, recurrent gliosarcoma